Location History:
- Ume.ang., SE (1993 - 1998)
- Holmsund, SE (2001)
- Umea, SE (1995 - 2003)
- Umeå, SE (2001 - 2023)
Company Filing History:
4 out of 25 
2 out of 5 
2 out of 2,489 
Years Active: 1993-2023
Title: Thomas Edlund: Pioneering Innovations in Molecular Biology
Introduction
Thomas Edlund is a distinguished inventor based in Umeå, Sweden, known for his significant contributions to molecular biology and pharmaceutical formulations. With a remarkable portfolio that includes 11 patents, Edlund's work is pivotal in advancing treatments for various medical conditions.
Latest Patents
Among his recent innovations, Edlund has developed formulations involving an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide. This compound is particularly useful in the treatment or prevention of disorders that can be ameliorated by the activation of AMPK. Another noteworthy patent from Edlund pertains to the discovery of a novel transcriptional regulatory factor in eukaryotic cells, referred to as 'Insulin Promoter Factor 1' or 'Ipf1'. This factor has promising applications related to insulin regulation in mammalian cells.
Career Highlights
Thomas Edlund has an impressive career trajectory that includes working with innovative companies such as Symbicom Aktiebolag and Ontogeny, Inc. His experience in these organizations has allowed him to apply his expertise in developing groundbreaking solutions in the life sciences domain.
Collaborations
Throughout his career, Edlund has collaborated with notable scientists, including Stefan Marklund and Thomas M. Jessell. These partnerships have further enriched his research, leading to the advancement of several key innovations in his field.
Conclusion
Thomas Edlund's inventive mind and dedication to scientific research continue to shape the landscape of molecular biology. His latest patents underscore his commitment to finding innovative solutions to complex medical challenges, making him a prominent figure in the world of biotechnology.